migalastat has been researched along with Sandhoff Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baek, RC; Bronson, RT; Butters, TD; Denny, CA; Heinecke, KA; Kim, YP; Loh, KS; Platt, FM; Seyfried, TN | 1 |
| Arthur, JR; Lee, JP; Seyfried, TN; Snyder, EY | 1 |
| Andersson, U; Borja, MC; Butters, TD; Dwek, RA; Jeyakumar, M; Platt, FM; Smith, D | 1 |
| Borja, MC; Butters, TD; Dwek, RA; Jeyakumar, M; Neville, DC; Platt, FM; Smith, DA; Williams, IM | 1 |
| Baek, RC; Butters, TD; Clark, D; Clarke, J; Dwek, RA; Fu, G; Gonzalez, R; Jeyakumar, M; Lee, JP; Lee, PJ; Lipton, SA; McKercher, S; Meerloo, J; Muller, FJ; Park, KI; Platt, FM; Rose, H; Schwartz, P; Seyfried, TN; Snyder, EY; Takahashi, H; Tong, G; Wenger, D | 1 |
| Baek, RC; Kasperzyk, JL; Platt, FM; Seyfried, TN | 1 |
6 other study(ies) available for migalastat and Sandhoff Disease
| Article | Year |
|---|---|
Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
Topics: 1-Deoxynojirimycin; 3-Hydroxybutyric Acid; Analysis of Variance; Animals; beta-N-Acetylhexosaminidases; Blood Glucose; Body Weight; Brain; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Diet, Ketogenic; Eating; G(M2) Ganglioside; Lipid Metabolism; Mice; Mice, Knockout; Myelin Sheath; Purkinje Cells; Sandhoff Disease | 2010 |
Therapeutic effects of stem cells and substrate reduction in juvenile Sandhoff mice.
Topics: 1-Deoxynojirimycin; Animals; beta-N-Acetylhexosaminidases; G(M2) Ganglioside; Hexosaminidase B; Mice; Neural Stem Cells; Sandhoff Disease | 2012 |
Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
Topics: 1-Deoxynojirimycin; Animals; Behavior, Animal; beta-N-Acetylhexosaminidases; Body Weight; Brain; Disease Models, Animal; Female; Gangliosides; Life Expectancy; Liver; Male; Mice; Mice, Mutant Strains; Sandhoff Disease | 2004 |
NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
Topics: 1-Deoxynojirimycin; Age Factors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Behavior, Animal; Blotting, Western; Brain; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Glutathione; Histocompatibility Antigens Class II; Immunohistochemistry; Isoenzymes; Lipid Peroxidation; Mice; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Prostaglandin-Endoperoxide Synthases; Psychomotor Performance; Sandhoff Disease; Spinal Cord; Survival Rate; Time Factors; Vitamin A | 2004 |
Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease.
Topics: 1-Deoxynojirimycin; Animals; beta-N-Acetylhexosaminidases; Brain; Embryonic Stem Cells; Humans; Immunohistochemistry; Mice; Mice, Knockout; Microglia; Neurons; Patch-Clamp Techniques; Sandhoff Disease; Stem Cell Transplantation | 2007 |
N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
Topics: 1-Deoxynojirimycin; Animals; Animals, Newborn; beta-Hexosaminidase alpha Chain; Brain; Brain Chemistry; Disease Models, Animal; Down-Regulation; G(M2) Ganglioside; Gangliosides; Glycosphingolipids; Mice; Mice, Knockout; Nerve Degeneration; Neuraminidase; Sandhoff Disease; Treatment Outcome | 2008 |